{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:28:17Z","timestamp":1790785697764,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Cancer Research Center, Faculty of Medicine, Ramathibodi Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00381-017-3409-y","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T06:41:37Z","timestamp":1493016097000},"page":"893-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan"],"prefix":"10.1007","volume":"33","author":[{"given":"Nongnuch","family":"Sirachainan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atthaporn","family":"Boongird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiti","family":"Swangsilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wipawi","family":"Klaisuban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apasri","family":"Lusawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"3409_CR1","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1002\/cncr.24663","volume":"115","author":"I Qaddoumi","year":"2009","unstructured":"Qaddoumi I, Sultan I, Gajjar A (2009) Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the surveillance, epidemiology, and end results database. Cancer 115:5761\u20135770","journal-title":"Cancer"},{"key":"3409_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1215\/S1152851703000097","volume":"5","author":"IF Pollack","year":"2003","unstructured":"Pollack IF, Boyett JM, Yates AJ, Burger PC, Gilles FH, Davis RL et al (2003) The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro-oncol 5:197\u2013207","journal-title":"Neuro-oncol"},{"key":"3409_CR3","doi-asserted-by":"crossref","unstructured":"Sposto R, Ertel IJ, Jenkin RDT, Boesel CP, Venes JL, Ortega JA et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neuro-Oncol 7:165\u2013177","DOI":"10.1007\/BF00165101"},{"key":"3409_CR4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0883073808321765","volume":"23","author":"NG Gottardo","year":"2008","unstructured":"Gottardo NG, Gajjar A (2008) Chemotherapy for malignant brain tumors of childhood. J Child Neurol 23:1149\u20131159","journal-title":"J Child Neurol"},{"key":"3409_CR5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-005-7409-5","volume":"76","author":"A Broniscer","year":"2006","unstructured":"Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC et al (2006) Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neuro-Oncol 76:313\u2013319","journal-title":"J Neuro-Oncol"},{"key":"3409_CR6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/cncr.11306","volume":"97","author":"TF Cloughesy","year":"2003","unstructured":"Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H et al (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97:2381\u20132386","journal-title":"Cancer"},{"key":"3409_CR7","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516\u20131525","journal-title":"J Clin Oncol"},{"key":"3409_CR8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-008-9749-4","volume":"92","author":"M Santisteban","year":"2009","unstructured":"Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM et al (2009) Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neuro-Oncol 92:165\u2013175","journal-title":"J Neuro-Oncol"},{"key":"3409_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1014532202188","volume":"56","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuro-Oncol 56:183\u2013188","journal-title":"J Neuro-Oncol"},{"key":"3409_CR10","doi-asserted-by":"crossref","unstructured":"Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncol 8:189\u2013193","DOI":"10.1215\/15228517-2005-010"},{"key":"3409_CR11","doi-asserted-by":"crossref","unstructured":"Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G (2007) Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 25 (18S, Part 1, June 20 Suppl: Abstr 2006)","DOI":"10.1200\/jco.2007.25.18_suppl.2006"},{"key":"3409_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/cbr.2013.1591","volume":"29","author":"R Cabanas","year":"2014","unstructured":"Cabanas R, Saurez G, Alert J, Reyes A, Valdes J, Gonzalez MC et al (2014) Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility. Cancer Biother Radiopharm 29:173\u2013178","journal-title":"Cancer Biother Radiopharm"},{"key":"3409_CR13","unstructured":"National Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria v3.0 (CTCAE) Published 9 August 2006. ctep.cancer.gov \/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"3409_CR14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4161\/cbt.28021","volume":"15","author":"MT Solomon","year":"2014","unstructured":"Solomon MT, Miranda N, Jorrin E, Chon I, Marinello JJ, Alert J et al (2014) Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. Cancer Biol Ther 15:504\u2013509","journal-title":"Cancer Biol Ther"},{"key":"3409_CR15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1471-2407-13-299","volume":"13","author":"MT Solomon","year":"2013","unstructured":"Solomon MT, Selva JC, Figueredo J, Vaguer J, Toledo C, Quintanal N et al (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:299","journal-title":"BMC Cancer"},{"key":"3409_CR16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cncr.24730","volume":"116","author":"JE Wolff","year":"2010","unstructured":"Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T et al (2010) Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 116:705\u2013712","journal-title":"Cancer"},{"key":"3409_CR17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14712598.2011.546341","volume":"11","author":"M Massimino","year":"2011","unstructured":"Massimino M, Bode U, Biassoni V, Fleischhack G (2011) Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 11:247\u2013256","journal-title":"Expert Opin Biol Ther"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00381-017-3409-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-017-3409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-017-3409-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T03:57:43Z","timestamp":1601956663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00381-017-3409-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3409"],"URL":"https:\/\/doi.org\/10.1007\/s00381-017-3409-y","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]}}}